The online version of this article (doi:10.1186/s12883-017-0844-z) contains supplementary material, which is available to authorized users.
Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed.
A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared.
A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001).
Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence.
Additional file 1: MS-related healthcare resource use before and during fampridine treatment. Description of data: The additional file includes an overview of the MS-related healthcare resource use in the pre- and post-index period in a tabular format. (DOCX 17 kb)12883_2017_844_MOESM1_ESM.docx
Van Asch P. Impact of mobility impairment in multiple sclerosis 2-patients’ perspectives. Eur Neurol Rev. 2011;6(2):115–20. CrossRef
EPAR summary for the public - Fampyra (fampridine) - EMA/430040/2011, EMEA/H/C/002097 [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002097/WC500109958.pdf]. Accessed 1 July 2016.
Deutsche Gesellschaft für Neurologie (German Neurological Society). Diagnose und therapie der multiplen sklerose. 2014. Leitlinie S2e. AWMF-Registernummer: 030/050 2014.
Hoer A, Schiffhorst G, Zimmermann A, Fischaleck J, Gehrmann L, Ahrens H, Carl G, Sigel KO, Osowski U, Klein M, et al. Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. BMC Health Serv Res. 2014;14:381. CrossRefPubMedPubMedCentral
Consumer Price Index and Inflation Rate. [ https://www.destatis.de/EN/FactsFigures/NationalEconomyEnvironment/Prices/ConsumerPriceIndices/ConsumerPriceIndices.html].
Jara M, Sidovar MF, Henney HR. Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Ther Clin Risk Manag. 2015;11:1–7. PubMed
Zusammenfassende Dokumentation über die Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V - Fampridin, Stand: 28. November 2012 [ https://www.g-ba.de/informationen/nutzenbewertung/14/#tab/beschluesse].
Anlage III - Vorlage zur Abgabe einer schriftlichen Stellungnahme zur Nutzenbewertung nach § 35a SGB V Stellungnahme Arzneimittelkommission Fampridine Vergleichstherapie, 23.05.2012 [ http://www.akdae.de/Stellungnahmen/AMNOG/A-Z/Fampridin/Fampridin.pdf]. Accessed 1 July 2016.
Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44–52. PubMed
- Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
Jennifer Scarlet Haas
- BioMed Central